Natural product therapy for pulmonary arterial hypertension: Tanshinone IIA, one of the main components of Salvia miltiorrhiza, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 29/October/2017, 7.40 am

Molecular therapy for inflammation and arthritis: Docosahexaenoic acid (DHA) increases IL-9, increases IL-9 levels, increases proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up regualtion of its target genes, 29/October/2017, 7.10 am
October 29, 2017
Natural product-based therapy for Deafness: A therapeutic mix encompassing Lutein, Puerarin, Cholecalciferol  and DIM (LPCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  and improves hearing loss via up regulation of its target genes, 29/October/2017, 7.50 am
October 29, 2017
Show all

What they say:  

A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:   Natural product therapy for pulmonary arterial hypertension: Tanshinone IIA, one of the main components of Salvia miltiorrhiza, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3


Significance of the study:  

Tanshinone IIAby increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). 

Figure 1. Mechanistic insights into how Tanshinone IIA inhibits the development of pulmonary hypertension. Oleanolic acid, by inhibiting Notch-3 and its target gene Hes-5, functions as an anti-hypertensive agent.

Thus, pharmacological formulations encompassing “Tanshinone IIA  or its analogues, either alone or in combination with other drugs, may be used to treat pulmonary arterial hypertension.


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How Tanshinone IIA decreases the expression of Notch3 

Amount: $100#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Natural product therapy for pulmonary arterial hypertension: Tanshinone IIA, one of the main components of Salvia miltiorrhiza, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 29/October/2017, 7.40 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.